New Product - Blincyto
Blincyto (blinatumomab (rch)) is a bispecific T cell engager (BiTE) antibody construct that selectively binds with high affinity to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells). Blincyto is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B‑precursor acute lymphoblastic leukaemia (ALL). Blincyto is contraindicated in patients with known hypersensitivity to CHO cell derived proteins. Blincyto is available as a composite pack containing a powder for injection vial (containing blinatumomab (rch) 38.5 microgram) and an IV solution stabiliser vial.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629